At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Safety, Tolerability and Population Pharmacokinetics of CMX001 in Post-Transplant Subjects With BK Virus Viruria
In Brief
A Phase 2 clinical trial evaluating Placebo and Brincidofovir for Viruria. Completed, enrolled 29 participants across 15 sites.
Detailed Summary
This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus viruria.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsViruria
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2008
Enrollment StartNov 2009
Primary CompletionOct 2010
TodayJul 2026
First PostedNov 19, 2008
Enrollment StartNov 1, 2009
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.6 years ago
Interventions
Placebodrug
Brincidofovirdrug